Showing 1 - 5 results of 5 for search 'Marie-Christiane Vekemans', query time: 0.03s Refine Results
  1. 1
    Crystalglobulin-Associated Kidney Disease: A Case Report and Literature Review

    Crystalglobulin-Associated Kidney Disease: A Case Report and Literature Review by Sophie Leflot, Philippe Leroy, Nathalie Demoulin, Selda Aydin, Guy Touchard, Vincent Javaugue, Marie-Christiane Vekemans, Frank Bridoux, Johann Morelle

    Published 2022-05-01
    Get full text
    Article
  2. 2
    Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG

    Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG by Roland B. Walter, Megan Othus, Bob Löwenberg, Gert J. Ossenkoppele, Stephen H. Petersdorf, Thomas Pabst, Marie-Christiane Vekemans, Frederick R. Appelbaum, Harry P. Erba, Elihu H. Estey

    Published 2015-10-01
    Get full text
    Article
  3. 3
    Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

    Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice by Michel Delforge, Marie-Christiane Vekemans, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Vande Broek, Sophie Vandervennet, Sandra Van Hoorenbeeck, Evelien Moorkens, Danielle Strens, Joris Diels, Francesca Ghilotti, Benjamin Haefliger, Sander Dalhuisen, William Deraedt, Sébastien Anguille

    Published 2022-12-01
    Get full text
    Article
  4. 4
    P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY

    P877: IXAZOMIB DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE... by Kaz Groen, Claudia Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Paula F. Ypma, Sonja Zweegman

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context

    Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context by Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Annelies Verbrugge, Danny Buitenhuis, Sonia M. Cunha, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Niels W.C.J. van de Donk, Mark-David Levin, Paula F. Ypma, Sonja Zweegman

    Published 2023-09-01
    Get full text
    Article

Search Tools: